• Search
  • Helpdesk
  • Sales contact
  • Rare disease
    clinical trials

The barriers to advancing scientific research in rare disease are high due to the severity and disabling aspects of the condition, the lack of existing treatments, and the scarcity of adequate scientific data.
Rare disease clinical trials are often more complex than traditional clinical trial designs. They require significant additions, on top of conventional measures, to broaden the information collected and address aspects of the disease that are relevant to the patients and to their unique histories.

At Kayentis, we ensure the incorporation of meaningful outcomes, symptoms, and aspects of the disease that matter to patients and families.

Strengthen your rare disease clinical program with our eCOA early strategic support

With extensive experience in rare disease clinical research, we provide strong strategic advisory support from the very start of your clinical development plan.

Optimize your rare disease clinical trial with highly professional operational guidance

The development of innovative treatments targeting unmet medical needs requires experienced, dedicated teams and reliable partners:

Support your rare disease study patients with our patient engagement program

Rare disease patients are scarce, making their input to clinical research highly valued, and engaging with such patients every day is instrumental to the success of a clinical study:

Check our latest insights about rare disease trials

How important do Patient Reported Outcomes need to become to improve the success of rare disease clinical trials?

What rare disease patients and families want is a simpler life.Discover here what makes the relationship between the members

A patient association in rare diseases is first and foremost families who all have one thing in common: they

Our therapeutic areas

Oncology
Immunology-Inflammatory
Rare disease
Cardiology
Respiratory
Dermatology
Ophthalmology
Metabolic health
Metabolic health
Pediatric